Skip to main content

Canine treatment with SnET2 for photodynamic therapy

Publication ,  Journal Article
Frazier, DL; Milligan, AJ; Vo-dinh, T; Morgan, AR; Overholt, BF
Published in: Proceedings of SPIE - The International Society for Optical Engineering
January 1, 1990

Photodynamic therapy is a treatment technique that utilizes the photoactived species of a drug to destroy tumor tissue. To be successful, the drug must localize in tumor tissue preferentially over normal tissue and must be activated by light of a specific wavelength. Currently the only drug to be approved for clinical use is Hematoporphyrin Derivative (HpD) although a series of new drugs are being developed for use in the near future. One of the drugs belongs to a class called purpurins which display absorptions between 630-711 nm. Along with several other investigators, we are currently exploring the characteristics of a specific purpurin (SnET2) in normal and tumorous canine tissue. The use of this compound has demonstrated increased tumor control rates in spontaneous dog tumors. Preliminary pharmacokinetic studies have been performed on 6 normal beagle dogs. SnET2 (2 mg/kg) was injected intravenously over 10 minutes and blood was collected at 5, 15, 30, 45 minutes and at 1, 2, 4, 8, 12 and 24 hours following administration for determin-ation of drug concentration and calculation of pharmacokinetic parameters. Skin biopsies were collected at 1, 4, 8, 12 and 24 hours. Dogs were euthanized at 24 hours and tissues (liver, kidney muscle, esophagus, stomach, duodenum, jejunum, ileum, colon, adrenal gland, thyroid, heart, lung, urinary bladder, prostate, pancreas, eye, brain) were collected for drug measurement. Drug was shown to persist in liver and kidney for a prolonged period of time compared to other tissues. Knowledge of the pharmacokinetic properties of the drug will greatly add to the ability to treat patients with effective protocols.

Duke Scholars

Published In

Proceedings of SPIE - The International Society for Optical Engineering

DOI

ISSN

0277-786X

Publication Date

January 1, 1990

Volume

1203

Start / End Page

196 / 201

Related Subject Headings

  • 5102 Atomic, molecular and optical physics
  • 4009 Electronics, sensors and digital hardware
  • 4006 Communications engineering
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Frazier, D. L., Milligan, A. J., Vo-dinh, T., Morgan, A. R., & Overholt, B. F. (1990). Canine treatment with SnET2 for photodynamic therapy. Proceedings of SPIE - The International Society for Optical Engineering, 1203, 196–201. https://doi.org/10.1117/12.17665
Frazier, D. L., A. J. Milligan, T. Vo-dinh, A. R. Morgan, and B. F. Overholt. “Canine treatment with SnET2 for photodynamic therapy.” Proceedings of SPIE - The International Society for Optical Engineering 1203 (January 1, 1990): 196–201. https://doi.org/10.1117/12.17665.
Frazier DL, Milligan AJ, Vo-dinh T, Morgan AR, Overholt BF. Canine treatment with SnET2 for photodynamic therapy. Proceedings of SPIE - The International Society for Optical Engineering. 1990 Jan 1;1203:196–201.
Frazier, D. L., et al. “Canine treatment with SnET2 for photodynamic therapy.” Proceedings of SPIE - The International Society for Optical Engineering, vol. 1203, Jan. 1990, pp. 196–201. Scopus, doi:10.1117/12.17665.
Frazier DL, Milligan AJ, Vo-dinh T, Morgan AR, Overholt BF. Canine treatment with SnET2 for photodynamic therapy. Proceedings of SPIE - The International Society for Optical Engineering. 1990 Jan 1;1203:196–201.

Published In

Proceedings of SPIE - The International Society for Optical Engineering

DOI

ISSN

0277-786X

Publication Date

January 1, 1990

Volume

1203

Start / End Page

196 / 201

Related Subject Headings

  • 5102 Atomic, molecular and optical physics
  • 4009 Electronics, sensors and digital hardware
  • 4006 Communications engineering